{"name":"Adcentrx Therapeutics","slug":"adcentrx-therapeutics","ticker":"","exchange":"","domain":"","description":"Adcentrx Therapeutics is a biotechnology company focused on developing innovative therapies in the early stages of clinical development. The company currently has two drug candidates, ADRX-0706 and ADRX-0405, both in Phase 1 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADRX-0706","genericName":"ADRX-0706","slug":"adrx-0706","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADRX-0706","genericName":"ADRX-0706","slug":"adrx-0706","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1MN0VhQTdaM0V3bTlFS2ZVcVlYeWZIaUVNOHNZeWM3eEFxMUlWTHdWMU5ZakFZSTlnbFFENkZUNGRRTUMzNlM4bDZkd2s0T19OVkRYZUpsdWxEYkNmMEF3NjJB?oc=5","date":"2026-02-11","type":"pipeline","source":"Labiotech.eu","summary":"Eight biotech companies spearheading the antibody drug conjugate new wave - Labiotech.eu","headline":"Eight biotech companies spearheading the antibody drug conjugate new wave","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNV1BLV2JycUhJQjFJbVhRWHQwQlI5cXpHXzltZkFiUElZQWduVUhxTGF3ck9hVldjYVlmZWQ5WXd5dDFXV2RLQWhFc29mMUNWTnlmTGs0bnkyb3RlUWNrNlhlclY5elRyMy01VWNjS2dqMHl1V3pUT1RhWnZpc3BQMDVWUFgxcXkyLWUtSkp2eFliZ0kxNE5XbXlBcy1vWjIyTS1odk90M3NaN3Jqb1F4cnVzNjRwbzEyRnJKRmg2MzIySmdPZE9nNnhjZG93UHBGeUNpTVM0TEgtMGxDWEZRM2lyeEFZUXJLU1Z6MmV3?oc=5","date":"2025-07-08","type":"regulatory","source":"PR Newswire","summary":"U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer - PR Newswire","headline":"U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPbGJRZ0x2TktNZlZieDljOVlmZU8zVGxYYXZySWhEYmhSMTFjNkpzRExUSjRBUnlvUkZRcGIxWkVvVTB3OXdOYzFzUjA0WVhCMmdtci0yM2hDRTFRdzBiRmtMQU5EVXlFdVVZSG5MbWt1NFpQbGN3RXBIWVJJelpXMTIyWVA0YXNURnU3MXJGRGdVZ0xPZ0c3Rzc4VzZvc09CWWRRRGloZFpQYy1uYndVdF8xNF95RVJza1dLcGlqWTN1SFZxOW5GajBlSlJMN0tQNUJQWHN6REhRTlFiMGM5OXNqVVVxZ29HNmJiQ0Nuc3lWdldJdTVjVTJVWXdvRjJNYXJlX3VYUVU0cWtvZkE?oc=5","date":"2025-05-06","type":"pipeline","source":"PR Newswire","summary":"Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer - PR Newswire","headline":"Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNZ1dGLW4wZDdzTmYwX2k4UzFuUG1OcUcwNzljSzBtZ0V5c3Z1QkdsWFF2SlRnYVBDX3JvbmNPMGJIa0RNME1kNTRoMTVLeE1USm9LVF9yeXR1RXNwY2hyUTQ2NUhxdjVNM2RpSXRrUWNvcC05LXIyRHdLRVlaQ3dZczlYM3ppanZ3aDJzZU9FSFlNUUdyVEhWNkNwNVR4RnU1RncxcGZoLUhqRmRtU1NfNmNFelc2MUNCSTF1bDZzQlQ1X0ZUMnRZNDlRS2M0NGtxaFdJbnUwazB4d2lTbmRITUhB?oc=5","date":"2025-04-23","type":"trial","source":"PR Newswire","summary":"Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025 - PR Newswire","headline":"Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaWRibmEzdWJ6ajk5M19FNVBYUU15VzhVVmNxWVJCNmdzWWpyNURCb3RLaV9hT1NPMTNsSmJsUHk4R1UyLWFKeUxWaFZIVm9sUDVxYjQ0ajEtX2c1c3RQMUF5SEYtZTNrellHOVR2cTY1TWFBdnJHbF9Fbk90SzFTYUJsUDJobm9aZ2FFYnpWZEp5QVdpNkg2ZUpFak1wR0NXQkdvcnlkemF5dw?oc=5","date":"2025-03-24","type":"deal","source":"BioSpace","summary":"AbbVie Lawsuit Alleges That Partner Genmab \"Misappropriated” Trade Secrets - BioSpace","headline":"AbbVie Lawsuit Alleges That Partner Genmab \"Misappropriated” Trade Secrets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxQQ2ExRTNxVjRZaGlPRDhBaGFCbnZRM1IyY1d1X2Zxam1BQVkyOWRteXdkOWphRFhDeWFPSjlmdUpWX1lEUnNvbHNYM25QU1JNZzFUSWlvUThsTHA0cEkyazdsU1gzU1RFUjNaalB4RUdwQ0V5Q3JEQUxySnZIVTc3Umc4RDBkb0MzVE04dEpWc2ZvY0ZXZ0JfWFFyQlQ1WFRZdXRob3dCR2dEcnljWXozSzV2S3NkWF9LQUVPZlAyaTdzbUFLOV9MRENVUTBxNlFTcGFRN1BFUWlMMkpDSTdpOHVBWlI0aGY3eTdHMWRySnpMSHQzNF95dWt2RFdEeUtUOHBUNDNjZTRQR3l2RnFRSGVtckFubFJwZGY1cTVrTnUxMW1QRDhuWGozTG12Sk45V3YxNUZsdXhtU1ktX2V5ZVltaG45dUF1VER4bWUxRVFSc1Rs?oc=5","date":"2025-01-06","type":"trial","source":"PR Newswire","summary":"Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors - PR Newswire","headline":"Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNb3FZaXo4elJxTUNfN2c4NzBGSU9oSERXLS1SSEctM0lhak95WV9RSzhJZ1ZaeUdOTjlCYnVlRGdiTnhnRTRwWlJPNmNWaDU5Z3QtTkdrMVFnSXZhbENCOFZzZWZMVlFzdTYxdDByQjR5TmdweVRjRmw0N1NEQUVndUZBczJ2MjZRNlNJZ19WZEVoVE9HYjl6cEZJa2k1V25FU1haRFk4aw?oc=5","date":"2024-09-10","type":"pipeline","source":"BioSpace","summary":"Adcentrx Therapeutics Announces Formation of Scientific Advisory Board - BioSpace","headline":"Adcentrx Therapeutics Announces Formation of Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNYUZVLV9ucFNVc0JNYUFkV0g3Rzk0dVRwWE1PUEVmanNQa3ZvX0E3NEtWd0VaLWs2NkFlZnlFTGxnTXlWY0J4dTNERzl2UjNlX3VicWlvdVFXc3ROckllRk1mbzJQNWFaQXB4cW5UNk5OTjcxcGVfNlNTdTl5dGdOWjhKNy1LM2F5anhrbWpZdWJkaVI2TE4ydl8tNGd5elU?oc=5","date":"2024-03-06","type":"trial","source":"Oncology Pipeline","summary":"AACR 2024 preview – more companies pile into popular mechanisms | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"AACR 2024 preview – more companies pile into popular mechanisms | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOWFZJcENEa3dHV2N4M2VueHY4ZWpWdWJqX0tSNE1DZXNsdTZBQ2dCcnA0TjdlM3k1OHVXN0JGZDV0SGhnMWZIS3hrRWpSZHY0X1BzQlBNLXhKcFZzMy1HaXJBZm5OeU9BejNGNmVSdlV0SkNRVUNyRzhRYTNsaFdRYjBwRGlrV3Zid0o5Z29fbWJoTS1OZUFVaXZFTTVLYndONlZ3dGREQ0tocmljNG9ocFM1MA?oc=5","date":"2023-12-19","type":"pipeline","source":"reuters.com","summary":"AbbVie lawsuit says rival Adcentrx stole anti-cancer secrets - reuters.com","headline":"AbbVie lawsuit says rival Adcentrx stole anti-cancer secrets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxONWk4SXJ3MjN6cThtQ1paenMya3VVOHRCNzBUR1NjanNwYm9QdjlPTkVoQzdxY0tmSWdUNkZUZnlmLTdZaWJjdlZjUWp4Ui1scXQydDVuRGhfVVFkUGROaWtDQ1hJNXRTYkNlbnhTNkc4Z2JlcUVycHduTkZpRWgzWGJ5Z2c0U3JJeXhnT2NNb0dzdUFDN1ZWR0JEQlB5LVJ6MjU3ZGlFM3VqZTI0Z1FsOGcyX0tNRlNLdG8wM2tJQXVrdm91MFZsNHV2OVpiWThiTTYwOXpHMlJQUEJZelJqQ1gwTHd4NUJlT1FsLUhldVc?oc=5","date":"2023-04-24","type":"pipeline","source":"PR Newswire","summary":"Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures - PR Newswire","headline":"Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}